Company intelligence / Profile preview
Voyageur Pharmaceuticals Ltd.
Calgary, Alberta, Canadavoyageurpharmaceuticals.ca ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Voyageur has begun human testing of its barium contrast product line in January 2025, with phase one focusing on Canadian radiology centers for domestic market entry later in 2025. Phase two will gather data under FDA guidelines to secure U.S. licensing[5].
- Therapeutic areas
- OtherGastroenterologyInfectious Diseases
- Modalities
- Contrast media productsActive Pharmaceutical Ingredients (APIs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Applied Pharmaceutical Innovation (API)Rain Cage Carbon Inc.Unnamed multinational contrast media company (LOI signed)[5][7]
Beyond the preview
Go deeper on Voyageur Pharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Voyageur Pharmaceuticals Ltd..